Detlef Thielgen, CFO of UCB, said: "We are very pleased with the strong support UCB receives in Belgium and Luxembourg and together with the recent convertible bond issuance, this operation confirms our ability to access various international Capital Markets." For further information Richard Simpson, Investor Relations, UCB T+32.2.559.9494, richard.simpsonucb.com Michael Tuck-Sherman, Investor Relations, UCB T +32.2.559.9712, michael.tuck-shermanucb.com Nancy Nackaerts, External Communications, UCB T +32.473.864.414, nancy.nackaertsucb.com About UCB UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders.
Full Article at PR-Inside.com